ArticleThe New England journal of medicine2020
A Trial of Lopinavir-Ritonavir in Covid-19.
Article in The New England journal of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019.Frontiers in pharmacology · 2020Pooled it
- Using prescription medication utilization trends to evaluate health system resilience and inform future emergency preparedness.Journal of managed care & specialty pharmacy · 2026Article
- Learning in times of stress: Lessons from COVID-19 that will last throughout this century.European journal of internal medicine · 2022Article
- Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study.The Journal of infection · 2021Article
- Article
- Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.European journal of clinical pharmacology · 2021Article
- COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays.Medicinal research reviews · 2021Review
- Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.Journal of clinical medicine · 2020Review
- Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects.Frontiers in immunology · 2020Review
- COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.Frontiers in oncology · 2020Article
- Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies.Intervirology · 2020Review
- Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study.Frontiers in immunologyArticle
Corrections and comments
- Commented on by
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32369285What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.